XpresSpa Group, Inc. announced that effective February 3, 2020, Mr. Robert Weinstein has been appointed to the Company’s Board of Directors and also named Chairman of the Audit Committee of the Board. He replaces Mr. Salvatore Giardina, who had previously served in those roles since May 2016, but has chosen to retire from the Board to spend more time on other commitments and pursuits. The company has made plans for a smooth transition. Mr. Weinstein is a finance and accounting senior executive with over 30 years of “hands-on” public and private company management, investment banking and private equity investing experience. He is recognized as a relationship savvy, proactive executive officer and principal with a focus on building sustainable shareholder value. Since 2012, Mr. Weinstein has served as Chief Financial Officer of Neurotrope, Inc. which focuses on developing new therapies for the treatment of rare diseases and Alzheimer’s disease. In his role, he manages internal and external accounting, finance, fundraising, budgeting, compliance and risk management, investor relations, information technology, human resources and cash management.